PIPGEN - PhD Project 11: Understanding the role of activated PI3Kδ mutations in B cell lymphoma.
Research · University of Cambridge > UK
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
Patients with APDS are at increased risk of developing B cell lymphoma. ESR11 will characterise a novel mouse model of B cell lymphoma driven by activated PI3Kδ and BCL6. The student will determine the sensitivity of these B cells to clinically approved inhibitors, such as Idealisib, Ibrutinib and Venetoclax. ESR11 will also develop protocols to initiate a CRISPR/Cas9-based screen to fine additional vulnerabilities in these B cell lines. Moreover, the student will determine how different T cell subsets can either promote or suppress lymphoma development with relevance to cancer immunotherapy.
Host: University of Cambridge (UCAM), UK.
Supervisor: Klaus Okkenhaug.
Doctoral programme: University of Cambridge.
Envisioned secondments: CIC bioGUNE, Josep Carreras Institute.